Read our latest updates & insights

Magellan Rx Management announced that its oncology biosimilar medical benefit drug management solution has saved customers over US$40 million, with greater savings expected as the market shift to biosimilars accelerates.

Bio-Thera announced it has initiated Ph III trials of BAT2506 (golimumab biosimilar).

MSD released new data on Keytruda® (pembrolizumab) in combination with Lenvima® (levatinib) versus sunitinib in patients with advanced renal cancer. MSD said that the results reinforced the combination of pembrolizumab and levatinib as a potential new treatment option for r...

Celltrion launched Remsima SC® (subcutaneous infliximab biosimilar) in Canada.  Remsima SC® is indicated for the treatment of rheumatoid arthritis.

The Korea Herald has reported that Celltrion will launch Yuflyma® in the EU in June.  Citing ‘industry sources’ and a Celltrion official, the article discloses that Celltrion will initially launch Yuflyma® in six EU countries including Spain, before launching in an addition...